Back to Search Start Over

Detachable microfluidic device implemented with electrochemical aptasensor (DeMEA) for sequential analysis of cancerous exosomes

Authors :
Hogyeong Gwak
Sudesna Chakravarty
Junmoo Kim
Min-Ho Lee
Kyung A. Hyun
Sunyoung Park
Hyo Il Jung
Seung Il Kim
Mohsen Mohammadniaei
Leila Kashefi-Kheyrabadi
Source :
Biosensors and Bioelectronics. 169:112622
Publication Year :
2020
Publisher :
Elsevier BV, 2020.

Abstract

The quantification of cancer-derived exosomes has a strong potential for minimally invasive diagnosis of cancer during its initial stage. As cancerous exosomes form a small fraction of all the exosomes present in blood, ultra-sensitive detection is a prerequisite for the development of exosome-based cancer diagnostics. Herein, a detachable microfluidic device implemented with an electrochemical aptasensor (DeMEA) is introduced for highly sensitive and in-situ quantification of cancerous exosomes. To fabricate the aptasensor, a nanocomposite was applied on the electrode surface followed by electroplating of gold nanostructures. Subsequently, an aptamer against an epithelial cell adhesion molecule is immobilized on the electrode surface to specifically detect cancer-specific exosomes. A microfluidic vortexer is then constructed and implemented in the sensing system to increase the collision between the exosomes and sensing surface using hydrodynamically generated transverse flow. The microfluidic vortexer was integrated with the aptasensor via a 3D printed magnetic housing. The detachable clamping of the two different devices provides an opportunity to subsequently harvest the exosomes for downstream analysis. The DeMEA has high sensitivity and specificity with an ultra-low limit of detection of 17 exosomes/μL over a wide dynamic range (1 × 102 to 1 × 109) exosomes/μL in a short period. As proof of the concept, the aptasensor can be separated from the 3D printed housing to harvest and analyze the exosomes by real-time polymerase chain reaction. Moreover, the DeMEA quantifies the exosomes from plasma samples of patients with breast cancer at different stages of the disease. The DeMEA provides a bright horizon for the application of microfluidic integrated biosensors for the early detection of cancerous biomarkers.

Details

ISSN :
09565663
Volume :
169
Database :
OpenAIRE
Journal :
Biosensors and Bioelectronics
Accession number :
edsair.doi.dedup.....0f6c4ed7a86fe592b58c58ee70f40c8e
Full Text :
https://doi.org/10.1016/j.bios.2020.112622